Inijaq

RSS

Authorised

This medicine is authorised for use in the European Union

tofacitinib
MedicineHumanAuthorised

Norwegian is available via eTranslation, the European Commission's machine translation service.

Translate to Norwegian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

Inijaq is a medicine used to treat:

  • adults with moderate to severe rheumatoid arthritis, a disease that causes inflammation of the joints. Inijaq is used with another medicine, methotrexate, after treatment with one or more medicines known as disease-modifying anti-rheumatic drugs (DMARDs) has not worked well enough or has led to troublesome side effects. Inijaq can be taken on its own if patients cannot take methotrexate;
  • adults with psoriatic arthritis (red, scaly patches on the skin with inflammation of the joints). Inijaq is used together with methotrexate after treatment with one or more DMARDs has not worked well enough or has led to troublesome side effects;
  • children from two years of age with active polyarticular juvenile idiopathic arthritis (pJIA) or juvenile psoriatic arthritis, a subtype of juvenile idiopathic arthritis (JIA), which is a long-term disease that causes joint pain and inflammation in children. Inijaq is used after treatment with one or more DMARDs has not worked well enough. Inijaq can be taken together with methotrexate or on its own if patients cannot take methotrexate;
  • adults with moderate to severe ulcerative colitis, a disease that causes inflammation and ulcers (sores) in the lining of the gut, after treatment with other medicines has not worked well, has stopped working or has led to troublesome side effects;
  • adults with ankylosing spondylitis, a disease that causes inflammation of the joints of the spine, after treatment with other medicines has not worked well enough.

Inijaq contains the active substance tofacitinib and is a ‘generic medicine’. This means that Inijaq contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Inijaq is Xeljanz. 

Inijaq is available as film-coated tablets to be taken by mouth twice a day. 

Treatment may be stopped in patients who develop an infection, which is a known side effect of the medicine, or in those with abnormal levels of red blood cells or certain white blood cells.

Inijaq can only be obtained with a prescription. Treatment should be started and supervised by a specialist doctor experienced in treating the relevant condition.

For more information about using Inijaq, see the package leaflet or contact your doctor or pharmacist.

The active substance in Inijaq, tofacitinib, works by blocking the action of enzymes known as Janus kinases. These enzymes play an important role in the process of inflammation that occurs in rheumatoid, psoriatic or juvenile idiopathic arthritis and ulcerative colitis. By blocking the enzymes’ action, tofacitinib helps reduce the inflammation and other symptoms of these diseases.

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Xeljanz, and do not need to be repeated for Inijaq.

As for every medicine, the company provided studies on the quality of Inijaq. There was no need for ‘bioequivalence’ studies to investigate whether Inijaq is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because the composition of Inijaq is very similar to the reference medicine’s and, based on the characteristics of tofacitinib and laboratory tests comparing Inijaq and Xeljanz, the active substance in both products is expected to be absorbed in the same way.

Studies carried out with Inijaq are described in more detail in the medicine’s assessment report.

Because Inijaq is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The European Medicines Agency concluded that, in accordance with EU requirements, Inijaq has been shown to be comparable to Xeljanz. Therefore, the Agency’s view was that, as for Xeljanz, the benefits of Inijaq outweigh the identified risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Inijaq have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Xeljanz, such as materials for healthcare professionals and patients about the medicine’s side effects, also apply to Inijaq where appropriate. 

As for all medicines, data on the use of Inijaq are continuously monitored. Suspected side effects reported with Inijaq are carefully evaluated and any necessary action taken to protect patients.

Inijaq received a marketing authorisation valid throughout the EU on 12 November 2026.

български (BG) (193.86 KB - PDF)

Vis

español (ES) (178.78 KB - PDF)

Vis

čeština (CS) (190.84 KB - PDF)

Vis

dansk (DA) (176.39 KB - PDF)

Vis

Deutsch (DE) (180.46 KB - PDF)

Vis

eesti (ET) (172.99 KB - PDF)

Vis

ελληνικά (EL) (192.86 KB - PDF)

Vis

français (FR) (177.71 KB - PDF)

Vis

hrvatski (HR) (191.6 KB - PDF)

Vis

italiano (IT) (175.8 KB - PDF)

Vis

latviešu (LV) (198.49 KB - PDF)

Vis

lietuvių (LT) (190.45 KB - PDF)

Vis

magyar (HU) (192.69 KB - PDF)

Vis

Malti (MT) (190.55 KB - PDF)

Vis

Nederlands (NL) (177.79 KB - PDF)

Vis

polski (PL) (196.4 KB - PDF)

Vis

português (PT) (177.36 KB - PDF)

Vis

română (RO) (187.46 KB - PDF)

Vis

slovenčina (SK) (191.43 KB - PDF)

Vis

slovenščina (SL) (189.91 KB - PDF)

Vis

suomi (FI) (173.9 KB - PDF)

Vis

svenska (SV) (174.99 KB - PDF)

Vis

Product information

български (BG) (933.65 KB - PDF)

Vis

español (ES) (1 MB - PDF)

Vis

čeština (CS) (1.03 MB - PDF)

Vis

dansk (DA) (753.29 KB - PDF)

Vis

Deutsch (DE) (780.19 KB - PDF)

Vis

eesti (ET) (811.91 KB - PDF)

Vis

ελληνικά (EL) (909.92 KB - PDF)

Vis

français (FR) (925.84 KB - PDF)

Vis

hrvatski (HR) (1.14 MB - PDF)

Vis

italiano (IT) (922.55 KB - PDF)

Vis

latviešu (LV) (865.89 KB - PDF)

Vis

lietuvių (LT) (1.09 MB - PDF)

Vis

magyar (HU) (957.24 KB - PDF)

Vis

Malti (MT) (944.41 KB - PDF)

Vis

Nederlands (NL) (942.94 KB - PDF)

Vis

polski (PL) (942.74 KB - PDF)

Vis

português (PT) (821.9 KB - PDF)

Vis

română (RO) (1.08 MB - PDF)

Vis

slovenčina (SK) (1.11 MB - PDF)

Vis

slovenščina (SL) (875.16 KB - PDF)

Vis

suomi (FI) (938.77 KB - PDF)

Vis

svenska (SV) (828.96 KB - PDF)

Vis

Íslenska (IS) (894.22 KB - PDF)

Vis

norsk (NO) (870.21 KB - PDF)

Vis
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (47.9 KB - PDF)

Vis

español (ES) (39.3 KB - PDF)

Vis

čeština (CS) (39.34 KB - PDF)

Vis

dansk (DA) (37.32 KB - PDF)

Vis

Deutsch (DE) (38.15 KB - PDF)

Vis

eesti (ET) (37.95 KB - PDF)

Vis

ελληνικά (EL) (54.79 KB - PDF)

Vis

français (FR) (36.56 KB - PDF)

Vis

hrvatski (HR) (98.06 KB - PDF)

Vis

italiano (IT) (37.24 KB - PDF)

Vis

latviešu (LV) (54.91 KB - PDF)

Vis

lietuvių (LT) (57.36 KB - PDF)

Vis

magyar (HU) (56.37 KB - PDF)

Vis

Malti (MT) (54.25 KB - PDF)

Vis

Nederlands (NL) (37.28 KB - PDF)

Vis

polski (PL) (51.41 KB - PDF)

Vis

português (PT) (39.67 KB - PDF)

Vis

română (RO) (55.17 KB - PDF)

Vis

slovenčina (SK) (53.07 KB - PDF)

Vis

slovenščina (SL) (56.26 KB - PDF)

Vis

suomi (FI) (36.95 KB - PDF)

Vis

svenska (SV) (35.91 KB - PDF)

Vis

Íslenska (IS) (37.17 KB - PDF)

Vis

norsk (NO) (36.71 KB - PDF)

Vis

Product details

Name of medicine
Inijaq
Active substance
tofacitinib citrate
International non-proprietary name (INN) or common name
tofacitinib
Therapeutic area (MeSH)
  • Arthritis, Rheumatoid
  • Colitis, Ulcerative
  • Arthritis, Juvenile
  • Arthritis, Psoriatic
  • Spondylitis, Ankylosing
Anatomical therapeutic chemical (ATC) code
L04AF01

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Rheumatoid arthritis 

Tofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). 

Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.  

Psoriatic arthritis 

Tofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.  

Ankylosing spondylitis 

Tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.  

Ulcerative colitis 

Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.  

Juvenile idiopathic arthritis (JIA) 

Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs. 

Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.

Authorisation details

EMA product number
EMEA/H/C/006698

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Gedeon Richter Plc.

Gyomroi ut 19-21
1103 Budapest
Hungary

Opinion adopted
17/09/2026
Opinion status
Positive
Marketing authorisation issued
12/11/2026

Assessment history

This page was last updated on

Share this page